AbbVie ABBV

NYS: ABBV | ISIN: US00287Y1091   8/12/2025
223,12 USD (-1,31%)
(-1,31%)   8/12/2025

2 december 2025 · AbbVie to Feature New Data at ASH 2025 Showcasing Continued Advances Across Novel Treatment Modalities in Multiple Blood Cancers · Persbericht

2 december 2025 · À l'occasion du 19e Congrès européen sur les céphalées, AbbVie va présenter les données de la phase 3 d'ECLIPSE démontrant la supériorité de l'atogépant (AQUIPTA®) par rapport au placebo dans le soulagement complet de la douleur pour le traitement aigu de la migraine · Persbericht

24 november 2025 · AbbVie to Present at the Piper Sandler 37th Annual Healthcare Conference · Persbericht

18 november 2025 · AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma · Persbericht

14 november 2025 · AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer · Persbericht

13 november 2025 · AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™ · Persbericht

12 november 2025 · Allergan Aesthetics Unveils New Data at 2025 American Society for Dermatologic Surgery Annual Meeting Showcasing Transformative Innovation and Portfolio Excellence · Persbericht

31 oktober 2025 · AbbVie Reports Third-Quarter 2025 Financial Results · Persbericht

29 oktober 2025 · The One & Only BOTOX® Cosmetic (onabotulinumtoxinA) Day Returns November 19 with the Biggest Celebration of the Year · Persbericht

29 oktober 2025 · AbbVie Announces Positive Topline Results from Phase 3 Pivotal Studies Evaluating Upadacitinib (RINVOQ®) in Adults and Adolescents with Vitiligo · Persbericht

28 oktober 2025 · Allergan Aesthetics and Girls Inc., in Partnership with SkinSpirit, Inspire Future Women Leaders in STEM · Persbericht

21 oktober 2025 · The Confidence Project by BOTOX® Cosmetic (onabotulinumtoxinA) Unveils This Year's Grant Recipients · Persbericht

20 oktober 2025 · RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF Inhibitor · Persbericht

20 oktober 2025 · Europees aandelennieuws · Bolero.be

Novo Nordisk benoemt Greg Miley tot wereldwijd hoofd corporate affairs. De Deense farmaceut heeft de Amerikaanse farmabestuurder Greg Miley aangesteld als wereldwijd hoofd corporate affairs, met als doel de relaties met...

17 oktober 2025 · AbbVie Completes Acquisition of Gilgamesh Pharmaceuticals' Bretisilocin · Persbericht

17 oktober 2025 · Beursnieuws België en Nederland · Bolero.be

Aedifica neemt woonzorgcentrum in Haulerwijk over voor 13 miljoen euro Aedifica: de Belgische zorgvastgoedinvesteerder neemt een volledig operationeel woonzorgcentrum over in Haulerwijk voor circa 13 miljoen euro. De investering...

13 oktober 2025 · U.S. Food and Drug Administration (FDA) Approves Updated Indication Statement for RINVOQ® (upadacitinib) for the Treatment of Inflammatory Bowel Disease · Persbericht

13 oktober 2025 · AbbVie to Present New Data at ESMO 2025 Reinforcing Leadership in Advancing Targeted Therapies for Solid Tumors · Persbericht

9 oktober 2025 · SkinMedica® Debuts Reimagined Packaging and Unveils New HA5® Hydra Collagen Water Burst Moisturizer · Persbericht

6 oktober 2025 · AbbVie Announces Positive Topline Results from Phase 2 ELATE Trial Evaluating OnabotulinumtoxinA (BOTOX®) for the Treatment of Upper Limb Essential Tremor · Persbericht

Mijn selecties